medigraphic.com
Colegio de Medicina Interna de México.

2005, Número 1

<< Anterior Siguiente >>

Med Int Mex 2005; 21 (1)


Utilidad de la estimulación eléctrica en la insuficiencia cardiaca

Asensio LE, Orea TA, Castillo ML, Narváez DR, Dorantes GJ, Oseguera MJ

Idioma: Español
Referencias bibliográficas: 36
Paginas: 52-59
Archivo PDF: 147.38 Kb.


RESUMEN

La insuficiencia cardiaca es un problema de salud complejo que supone un tratamiento complicado. La estimulación eléctrica permite diversos tipos de tratamiento que, individualizados, inciden favorablemente en la calidad de vida y la clase funcional de los pacientes. Entre estas opciones terapéuticas está la resincronización biventricular que mejora la calidad de vida de los enfermos seleccionados, así como la supervivencia en ciertos grupos cuando se combina con desfibriladores automáticos implantables. En este trabajo se revisan las bases fisiopatológicas de la estimulación tricameral, así como las indicaciones actuales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Medscape Cardiology 2004: http://www.medscape.com/viewarticle/466090_1

  2. Guadalajara J, González S, Fernández C. Muerte súbita en insuficiencia cardiaca. Arch Inst Cardiol Mex 1999;69:80-88.

  3. Schocken D, Arrieta M, Leaverton P, Ross E. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-6.

  4. Ho K, Pinski J, Kannel W, Levy D. The epidemiology of congestive heart failure in Framingham Heart Study subjects. J Am Coll Cardiol 1993;22:5550-8.

  5. Hadelman G, Croft J, Giles W, Rashidee A. Hospitalization of patients with heart failure: national hospital discharge survey 1985-1995. Am Heart J 1999;137:352-60.

  6. Katz A. Heart failure. Pathophysiology, molecular biology and clinical management. 1st ed. Atlanta: Lippincott Williams and Wilkins, 2000;pp:1-33.

  7. Orea A, Castillo L. Programa Nacional de Registro de Insuficiencia Cardiaca (PRONARICA). Boletín 1, Nov, 2003.

  8. Hunt S, Baker D, Chin M. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. Circulation 2001;104:2996-3007.

  9. Katz A. Cytoskeletal abnormalities in the failing heart: Out on a limb? Circulation 2000;101(23):2672-3.

  10. Katz A. Proliferative signaling and disease progression in heart failure. Circulation 2002;66(3):225-31.

  11. Saxon L, De Marco T. Resynchronization therapy for geart failure. www.naspe.org/professional_education 2004

  12. Tomaselli G, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Research 1999;42(2):270-83.

  13. McAnulty H, Rahimtoola H, Murphy E, et al. Natural history of “high risk” bundle branch block: final report of a prospective study. N Engl J Med 1982;307(3):137-43.

  14. Baldasseroni S, Opasich C, Gorini M. Left bundle branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: A report from the Italian Network on Congestive Heart Failure. Am Heart J 2002;143:398-405.

  15. Gottipaty V, Krelis S, Fei L. The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic heart failure. J Am Coll Cardiol 1999;145A(Abstract):847-4.

  16. Xiao H, Lee C, Gibson D. Effect of left bundle branch block on diastolic function in dilated cardiomyopathy. Br Heart J 1991;66:443-7.

  17. Grines C, Bashore T, Boudoulas H, Olson S, Shafer P, Wooley C. Functional abnormalities in isolated left bundle branch block: The effect of intraventricular asynchrony. Circulation 1989;79:845-53.

  18. Xiao H, Brecker S, Gibson D. Effects of abnormal activation on the time course of left ventricular pressure in dilated cardiomyopathy. Br Heart J 1992;68:403-7.

  19. Yu C, Chau E, Sanderson J, Fan K, Tang M, Fung W, et al. Tissue doppler echocardiographic evidence of reverse remodeling and improved chronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002;105:438-45.

  20. Kass D, Chen C, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999;99:1567-73.

  21. Cleland J, Thackray S, Goodge L, Kaye G, Cooklin M. Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol 2002;13:S73-91.

  22. Stellbrink C, Auricchio A, Butter C, Sack S, Vogt J, Bocker D, et al. Pacing therapies in congestive heart failure II study. Am J Cardiol 2000;86(Suppl):138K-43K.

  23. Asensio E, Orea A, Castillo L, Narváez R, Dorantes J, Rebollar V, et al. Utilidad de la estimulación con marcapasos de doble cámara en una serie de pacientes con insuficiencia cardiaca congestiva. Med Int Mex 2004;20(2):85-90.

  24. Rosenqvist M, Isaaz K, Botvinick E. Relative importance of activation sequence compared to atrioventricular synchrony in left ventricular function. Am J Cardiol 1991;67:148-56.

  25. Cazeau S, Leclerq C, Lavergne T. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001:344:873-80.

  26. Brecker S, Xiao H, Sparrow J, Gibson D. Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet 1992;340:1308-12.

  27. Blanc J, Etienne Y, Gilard M, Mansourati J, Munier S, Boschat J, et al. Evaluation of different pacing sites in patients with severe heart failure: Results of an acute hemodynamic study. Circulation 1997;96:3273-7.

  28. Reuter S, Garrigue S, Bordachar P, Kobeissi A, Gaggini G, Jais P. Left ventricular pacing alters cardiac function during exercise compared with biventricular pacing: A mid-term prospective study by using a hemodynamic sensir. Pacing Clin Electrophysiol 2002;24(4, pt II):547.

  29. Garrigue S, Bader H, Reuter S, et al. QRS duration and morphology are not reliable parameters to identify heart failure patients with left ventricular dyssynchrony: An echocardiographic doppler tissue imaging study. Pacing Clin Electrophysiol 2002;24(4, pt II):547.

  30. Auricchio A, Stellbrink C, Sacks S for the PATH-CHF study group. The pacing for congestive heart failure (PATH CHF) study rationale, design and end-points of a prospective randomized multicenter study. Am J Cardiol 1999;83(suppl): 130D-5D.

  31. Cazeau S, Leclerq C for the MUSTIC investigators. The Multisite Stimulation in Cardiomyopathies (MUSTIC) Study investigators. Effects of multisite biventricular pacing inpatients with heart failure and intraventricular conduction delay. N Engl J Med 2001:344:873-80.

  32. Abraham W, Fisher W, Smith A for the MIRACLE study group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.

  33. VENTAK CHF/CONTAK CD: www.fda.org;CONATKCDCRT-Dsystem/PMA/P010012summary

  34. Bristow M, Feldman A, Saxon L. Heart failure management using implantable devices for ventricular resynchronization: Comparison of medical therapy, pacing and defibrillation in chronic heart failure (COMPANION) trial. J Card Fail 2000;6:276-85.

  35. Young J, Abraham W, Liem L, Leon A. Cardiac resynchronization therapy (CRT) benefits patients with ICD indications. Results of the InSync-ICD trial. Pacing Clin Electrophysiol 2002;25(pt II):694.

  36. Gregoratos G, Abrams J, Epstein A, Freedman R, Hayes D, Hlatky M, et al. ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices, www.naspe.org




2020     |     www.medigraphic.com